Nuvalent, Inc. (NUVL) — Stock Score Summary

Nuvalent, Inc. (NUVL) has a MoatMap StockRank of 22/100 based on Quality (34/100), Value (24/100), and Momentum (50/100) factor scores. The current signal is SELL. Nuvalent is a clinical-stage biotech company developing targeted therapies. While its pipeline is promising, it lacks commercialized products and relies heavily on third-party CDMOs, making it a casualty of rising CDMO pricing power rather than a beneficiary.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely designed, small molecule kinase inhibitors for patients with cancer. Its proprietary drug discovery platform enables the development of highly selective and potent therapies that can overcome resistance mechanisms in difficult-to-treat mutations. The company's innovative approach aims to address critical unmet needs in targeted oncology.

Key Financial Metrics

Price$89.86
Market Cap$8.6B
P/E (Forward)-22.59
Price/Book6.32
Return on Equity-41.2%
Return on Invested Capital-31.4%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-180M

Nuvalent, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nuvalent, Inc.’s (NUVL) StockRank?
MoatMap’s StockRank for Nuvalent, Inc. (NUVL) is 22/100, with a Sell signal. It is a composite of Quality (34), Value (24), and Momentum (50) factor ranks across MoatMap’s 19,000+ stock universe.
Does Nuvalent, Inc. have an economic moat?
Nuvalent, Inc. (NUVL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nuvalent, Inc. a buy, hold, or sell?
MoatMap’s current signal for Nuvalent, Inc. (NUVL) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nuvalent, Inc. in?
Nuvalent, Inc. (NUVL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNUVL deep dive reportAI ChampionsHow we score stocksSense-check another stock